BARC/PUB/2023/0537

 
 

Deoxyglucose-conjugated persistent luminescent nanoparticles for theragnostic application in fibrosarcoma tumor model

 
     
 
Author(s)

Sharma, K. S.; Melwani, P. K.; Yadav, H. D.; Joshi, R.; Shetake, N. G.; Dubey, A. K.; Singh, B. P.; Phapale, S.; Phadnis, P. P.; Vatsa, R. K.; Ningthoujam, R. S.; Pandey, B. N.
(ChD;RB&HSD;BOD)

Source

RSC Advances, 2023. Vol. 13: pp. 13240-13251

ABSTRACT

Deoxyglucose conjugated nanoparticles with persistent luminescence have shown theragnostic potential. In this study, deoxyglucose-conjugated nano-particles with persistent luminescence properties were synthesized, and their theragnostic potential was evaluated in fibrosarcoma cancer cells and a tumor model. The uptake of nano-formulation was found to be higher in mouse fibrosarcoma (WEHI-164) cells cultured in a medium without glucose. Nanoparticles showed a higher killing ability for cancer cells compared to normal cells. A significant accumulation of nanoparticles to the tumor site in mice was evident by the increased tumor/normal leg ratio, resulting in a significant decrease in tumor volume and weight. Histopathological studies showed a significant decrease in the number of dividing mitotic cells but a greater number of apoptotic/necrotic cells in nanoparticle-treated tumor tissues, which was correlated with a lower magnitude of Ki-67 expression (a proliferation marker). Consequently, our results showed the potential of our nano-formulation for cancer theragnosis.

 
 
SIRD Digital E-Sangrahay